|
1
|
Friedrich P, Ortiz R, Strait K, Fuentes S,
Gamboa Y, Arambú I, Ah-Chu-Sanchez M, London W, Rodríguez-Galindo
C, Antillón-Klussmann F, et al Central American Association of
Pediatric Hematologists Oncologists AHOPCA: Pediatric sarcoma in
Central America: outcomes, challenges, and plans for improvement.
Cancer. 119:871–879. 2013. View Article : Google Scholar
|
|
2
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morrow JJ and Khanna C: Osteosarcoma
genetics and epigenetics: emerging biology and candidate therapies.
Crit Rev Oncog. 20:173–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Admassi D: Osteosarcoma of medial cuniform
bone. Ethiop Med J. 47:305–308. 2009.
|
|
5
|
Husmann K, Ducommun P, Sabile AA, Pedersen
EM, Born W and Fuchs B: Signal transduction and downregulation of
C-MET in HGF stimulated low and highly metastatic human
osteosarcoma cells. Biochem Biophys Res Commun. 464:1222–1227.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee JA, Kim MS, Kim DH, Lim JS, Park KD,
Cho WH, Song WS, Lee SY and Jeon DG: Postoperative infection and
survival in osteosarcoma patients. Ann Surg Oncol. 16:147–151.
2009. View Article : Google Scholar
|
|
7
|
Martin H, Mali RS, Ma P, Chatterjee A,
Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte
V, et al: Pak and Rac GTPases promote oncogenic KIT-induced
neoplasms. J Clin Invest. 123:4449–4463. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Melzer J, Kraft KF, Urbach R and Raabe T:
The p21-activated kinase Mbt is a component of the apical protein
complex in central brain neuroblasts and controls cell
proliferation. Development. 140:1871–1881. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gu J, Li K, Li M, Wu X, Zhang L, Ding Q,
Wu W, Yang J, Mu J, Wen H, et al: A role for p21-activated kinase 7
in the development of gastric cancer. FEBS J. 280:46–55. 2013.
View Article : Google Scholar
|
|
10
|
Zhang HH, Zhang ZY, Che CL, Mei YF and Shi
YZ: Array analysis for potential biomarker of gemcitabine
identification in non-small cell lung cancer cell lines. Int J Clin
Exp Pathol. 6:1734–1746. 2013.PubMed/NCBI
|
|
11
|
Han K, Zhou Y, Gan ZH, Qi WX, Zhang JJ,
Fen T, Meng W, Jiang L, Shen Z and Min DL: p21-activated kinase 7
is an oncogene in human osteosarcoma. Cell Biol Int. 38:1394–1402.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Giroux V, Iovanna JL, Garcia S and Dagorn
JC: Combined inhibition of PAK7, MAP3K7 and CK2alpha kinases
inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts.
Cancer Gene Ther. 16:731–740. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gong W, An Z, Wang Y, Pan X, Fang W, Jiang
B and Zhang H: P21-activated kinase 5 is overexpressed during
colorectal cancer progression and regulates colorectal carcinoma
cell adhesion and migration. Int J Cancer. 125:548–555. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fromm B, Billipp T, Peck LE, Johansen M,
Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, et
al: A uniform system for the annotation of vertebrate microRNA
genes and the evolution of the human microRNAome. Annu Rev Genet.
49:213–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bai Y, Li J, Li J, Liu Y and Zhang B:
miR-615 inhibited cell proliferation and cell cycle of human breast
cancer cells by suppressing of AKT2 expression. Int J Clin Exp Med.
8:3801–3808. 2015.PubMed/NCBI
|
|
17
|
Shen F, Cai WS, Feng Z, Li JL, Chen JW,
Cao J and Xu B: miR-492 contributes to cell proliferation and cell
cycle of human breast cancer cells by suppressing SOX7 expression.
Tumour Biol. 36:1913–1921. 2015. View Article : Google Scholar
|
|
18
|
Cai K, Shen F, Cui JH, Yu Y and Pan HQ:
Expression of miR-221 in colon cancer correlates with prognosis.
Int J Clin Exp Med. 8:2794–2798. 2015.PubMed/NCBI
|
|
19
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar
|
|
20
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang J, Gusev Y, Aderca I, Mettler TA,
Nagorney DM, Brackett DJ, Roberts LR and Schmittgen TD: Association
of MicroRNA expression in hepatocellular carcinomas with hepatitis
infection, cirrhosis, and patient survival. Clin Cancer Res.
14:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen YJ, Wu H, Zhu JM, Li XD, Luo SW, Dong
L, Liu TT and Shen XZ: MicroRNA-18a modulates P53 expression by
targeting IRF2 in gastric cancer patients. J Gastroenterol Hepatol.
31:155–163. 2016. View Article : Google Scholar
|
|
23
|
Peng J: miR-638 a novel tumor suppressor
for triple-negative breast cancer. ProQuest/UMI. 2014.
|
|
24
|
Su J, Wang Q, Liu Y and Zhong M: miR-217
inhibits invasion of hepatocellular carcinoma cells through direct
suppression of E2F3. Mol Cell Biochem. 392:289–296. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He C, Xiong J, Xu X, Lu W, Liu L, Xiao D
and Wang D: Functional elucidation of miR-34 in osteosarcoma cells
and primary tumor samples. Biochem Biophys Res Commun. 388:35–40.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li T, Lu YY, Zhao XD, Guo HQ, Liu CH, Li
H, Zhou L, Han YN, Wu KC, Nie YZ, et al: MicroRNA-296-5p increases
proliferation in gastric cancer through repression of
Caudal-related homeobox 1. Oncogene. 33:783–793. 2014. View Article : Google Scholar
|
|
27
|
Liu X, Zhang J, Xie B, Li H, Shen J and
Chen J: MicroRNA-200 family profile: a promising ancillary tool for
accurate cancer diagnosis. Am J Ther. 23:e388–e397. 2016.
View Article : Google Scholar :
|
|
28
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wong N and Wang X: miRDB: an online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar :
|
|
30
|
Maragkakis M, Reczko M, Simossis VA,
Alexiou P, Papadopoulos GL, Dalamagas T, Giannopoulos G, Goumas G,
Koukis E, Kourtis K, et al: DIANA-microT web server: elucidating
microRNA functions through target prediction. Nucleic Acids Res.
37:W273–276. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Leonardo TR, Schultheisz HL, Loring JF and
Laurent LC: The functions of microRNAs in pluripotency and
reprogramming. Nat Cell Biol. 14:1114–1121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar :
|
|
34
|
Roderburg C and Luedde T: Circulating
microRNAs as markers of liver inflammation, fibrosis and cancer. J
Hepatol. 61:1434–1437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Y, Xing Y, Liang C, Hu L, Xu F and
Chen Y: Crucial microRNAs and genes of human primary breast cancer
explored by microRNA-mRNA integrated analysis. Tumour Biol.
36:5571–5579. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang J, Zhang Y, Yu C, Li Z, Pan Y and
Sun C: MicroRNA-492 expression promotes the progression of hepatic
cancer by targeting PTEN. Cancer Cell Int. 14:952014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Peng L, Zhu H, Wang J, Sui H, Zhang H, Jin
C, Li L, Xu T and Miao R: miR-492 is functionally involved in
oxaliplatin resistance in colon cancer cells LS174T via its
regulating the expression of CD147. Mol Cell Biochem. 405:73–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Markou A, Sourvinou I, Vorkas PA, Yousef
GM and Lianidou E: Clinical evaluation of microRNA expression
profiling in non small cell lung cancer. Lung Cancer. 81:388–396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wells CM and Jones GE: The emerging
importance of group II PAKs. Biochem J. 425:465–473. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He S, Feng M, Liu M, Yang S, Yan S, Zhang
W, Wang Z, Hu C, Xu Q, Chen L, et al: P21-activated kinase 7
mediates cisplatin-resistance of esophageal squamous carcinoma
cells with Aurora-A overexpression. PLoS One. 9:e1139892014.
View Article : Google Scholar : PubMed/NCBI
|
